Fatty Liver in Inflammatory Bowel Disease (IBD) Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00855907 |
Recruitment Status
: Unknown
Verified March 2009 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted
: March 5, 2009
Last Update Posted
: March 5, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Fatty liver is known to be one of the most frequent liver pathologies in IBD patients (35-40%). Despite this fact, there are only few publications that evaluated the prevalence of fatty liver in IBD patients. Moreover, the pathogenesis of this phenomenon in IBD has not been widely investigated.
The paradox of lean patients and fatty liver can be explained by high use of steroids, by rapid weight loss, and by the abundance of TNFα cytokine in IBD patients that causes insulin resistance.
The aim of the study:
To evaluate the frequency of fatty liver in a cohort of IBD patients and to learn its risk factors.
Methods:
One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will be recruited.
Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.
Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.
Condition or disease | Intervention/treatment |
---|---|
Inflammatory Bowel Disease Fatty Liver | Other: clinical evaluation |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Time Perspective: | Cross-Sectional |
Official Title: | Prevalence of Fatty Liver in Inflammatory Bowel Disease (IBD) Patients and Mechanisms Related to Inflammation and Fatty Liver |
Study Start Date : | March 2009 |
Estimated Primary Completion Date : | March 2010 |
Estimated Study Completion Date : | March 2011 |
Group/Cohort | Intervention/treatment |
---|---|
cases
IBD patients above the age of 18 years old, suffering from the disease for at least one year.
|
Other: clinical evaluation
Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome. Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography. |
- inflammation and metabolic status [ Time Frame: first visit ]
- Assessment of Fatty liver [ Time Frame: first visit ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- IBD patients above the age of 18 years old, suffering from the disease for at least one year.
Exclusion Criteria:
- Pregnant women,
- Patients suffering from ulcerative colitis after total colectomy,
- HIV patients,
- Patients suffering from other chronic liver disease,
- Patients suffering from cancer currently or in the past, OR
- Patients suffering from any other chronic severe diseases.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00855907
Contact: Nitsan Maharshak, MD | 972-3-6974282 | nitsan_maharshak@walla.com |
Israel | |
Tel Aviv Sourasky Medical center | Not yet recruiting |
Tel Aviv, Israel, 64239 | |
Contact: Nitsan Maharshak, MD 972-3-6974282 nitsan_maharshak@walla.com | |
Principal Investigator: Nitsan Maharshak, MD |
Responsible Party: | Principle investigator - Gastroenterologist, Tel Aviv Sourasky medical center |
ClinicalTrials.gov Identifier: | NCT00855907 History of Changes |
Other Study ID Numbers: |
TASMC-09-NM-593-CTIL |
First Posted: | March 5, 2009 Key Record Dates |
Last Update Posted: | March 5, 2009 |
Last Verified: | March 2009 |
Keywords provided by Tel-Aviv Sourasky Medical Center:
IBD inflammatory bowel disease fatty liver |
Additional relevant MeSH terms:
Intestinal Diseases Inflammatory Bowel Diseases Fatty Liver Gastrointestinal Diseases |
Digestive System Diseases Gastroenteritis Liver Diseases |